The gold standard in diagnosing prostate cancer (PCa) is pathological examination of biopsy cores. Still, false negative rates remain between 30-50%. Studies of cancer field effects suggest that tissue without histologically visualizable cancer cells has diagnostic value and could enlarge biopsy target regions. To map metabolic field effects in human prostates, we used HRMAS-MRS to analyze multiple tissue samples throughout entire removed cancer-positive prostates. Evaluation of metabolomic profiles of histologically-benign (Hb) tissue showed that Hb tissues at varying distances to PCa lesions have different metabolic profiles. Hb tissue enables differentiation between clinical parameters (Gleason Score, pathological stage, cancer-affected prostate %).